Bellerophon Therapeutics (Bellerophon Therapeutics) EPS (Basic) : $-0.84 (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics EPS (Basic)?

Bellerophon Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2023 was $-0.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.84.

Bellerophon Therapeutics's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.84.

Bellerophon Therapeutics's EPS without NRI for the three months ended in Sep. 2023 was $-0.17. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -0.85.

During the past 3 years, the average EPS without NRI Growth Rate was 15.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 35.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Bellerophon Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 60.40% per year. The lowest was -1.90% per year. And the median was 31.10% per year.

Bellerophon Therapeutics EPS (Basic) Historical Data

The historical data trend for Bellerophon Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics EPS (Basic) Chart

Bellerophon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

0.73

-2.95

-3.17

-1.87

-2.08

Bellerophon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Basic)	Get a 7-Day Free Trial															-0.53	-0.53	0.27	-0.42	-0.16

Bellerophon Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Bellerophon Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-19.831	-	0)	/	9.551
	=	-2.08

Bellerophon Therapeutics's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.921	-	0)	/	12.233
	=	-0.16

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84

Bellerophon Therapeutics (OTCPK:BLPH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Bellerophon Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

0HMP:UK

Address

184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059

Website

https://www.bellerophon.com

Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.

Executives

Puissance Life Science Opportunities Fund Vi	10 percent owner	950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin	director	53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang	director	C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder	director	C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah	officer: VP of Business Operations	C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker	officer: See Remarks	53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes	officer: See Remarks	PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim	officer: VP Reg. Affairs & Quality	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona	officer: Controller, (PFO & PAO)	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky	10 percent owner	C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c.	10 percent owner	1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc	10 percent owner	787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019